Stockscreener 앱 받기
38.63
0.21%
-0.08
전일 마감가:
$38.71
열려 있는:
$38.74
하루 거래량:
1.51M
Relative Volume:
0.45
시가총액:
$10.40B
수익:
$2.17B
순이익/손실:
$521.27M
주가수익비율:
21.82
EPS:
1.77
순현금흐름:
$633.79M
1주 성능:
+0.84%
1개월 성능:
-13.13%
6개월 성능:
+4.83%
1년 성능:
+49.84%
1일 변동 폭
$38.31
$38.85
1주일 범위
$37.40
$38.85
52주 변동 폭
$25.12
$49.62
Exelixis Inc Stock (EXEL) Company Profile
명칭
Exelixis Inc
전화
(650) 837-7000
주소
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
EXEL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
38.63 | 10.17B | 2.17B | 521.27M | 633.79M | 1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-08 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2024-09-19 | 개시 | UBS | Neutral |
| 2024-04-11 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2023-12-19 | 개시 | BTIG Research | Buy |
| 2023-12-15 | 개시 | Citigroup | Buy |
| 2023-09-26 | 개시 | H.C. Wainwright | Buy |
| 2023-08-22 | 재확인 | Oppenheimer | Outperform |
| 2023-08-08 | 개시 | SVB Securities | Market Perform |
| 2023-07-11 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-05-10 | 재개 | Piper Sandler | Overweight |
| 2023-03-09 | 개시 | Wells Fargo | Overweight |
| 2023-01-26 | 개시 | Credit Suisse | Outperform |
| 2022-10-18 | 개시 | JMP Securities | Mkt Outperform |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-11-03 | 재개 | Jefferies | Buy |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-15 | 개시 | H.C. Wainwright | Buy |
| 2021-05-18 | 재개 | Goldman | Sell |
| 2021-03-31 | 개시 | Credit Suisse | Outperform |
| 2021-03-12 | 개시 | Wolfe Research | Outperform |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-13 | 개시 | SunTrust | Buy |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-03-18 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | 개시 | Goldman | Neutral |
| 2018-09-10 | 개시 | Morgan Stanley | Underweight |
| 2018-05-11 | 재확인 | Needham | Buy |
| 2017-10-17 | 재확인 | Needham | Buy |
| 2017-10-17 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-16 | 재확인 | SunTrust | Buy |
| 2017-09-22 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-09-12 | 재확인 | Needham | Buy |
| 2017-07-14 | 개시 | SunTrust | Buy |
| 2017-03-31 | 개시 | Needham | Buy |
| 2017-03-16 | 개시 | Oppenheimer | Perform |
| 2017-02-28 | 다운그레이드 | Stifel | Buy → Hold |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2016-10-10 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | 재확인 | Stifel | Buy |
모두보기
Exelixis Inc 주식(EXEL)의 최신 뉴스
Exelixis (EXEL) Tumbles 16.8% as Q2 Earnings Disappoint - MSN
How to manage a losing position in Exelixis Inc.2025 Top Gainers & Stepwise Trade Signal Implementation - Newser
Developing predictive dashboards with Exelixis Inc. dataWeekly Volume Report & High Conviction Buy Zone Picks - Newser
Will Exelixis Inc. stock go up soonQuarterly Performance Summary & Daily Volume Surge Signals - Newser
Exelixis Inc. Flashes Rebound Signal in Oversold ConditionJuly 2025 Outlook & High Accuracy Investment Entry Signals - beatles.ru
Sector ETF performance correlation with Exelixis Inc.July 2025 Highlights & Daily Stock Trend Watchlist - Newser
When is the best time to exit Exelixis Inc.2025 Growth vs Value & Weekly Market Pulse Updates - Newser
Should you wait for a breakout in Exelixis Inc.Market Trend Report & Safe Capital Growth Tips - Newser
What candlestick patterns are forming on Exelixis Inc.Weekly Stock Analysis & Capital Efficiency Focused Ideas - Newser
Price momentum metrics for Exelixis Inc. explainedQuarterly Growth Report & Daily Entry Point Alerts - Newser
Will EXEL's Share Repurchase Program Boost Value for Investors? - sg.finance.yahoo.com
Can Exelixis Inc. Rally Enough to Break EvenJuly 2025 Opening Moves & Growth Focused Stock Reports - classian.co.kr
Is Exelixis Inc. stock forming a cup and handleBear Alert & Fast Gain Stock Trading Tips - thegnnews.com
Is Exelixis Inc. building a consolidation base2025 Big Picture & Real-Time Chart Breakout Alerts - Newser
BofA Hikes Exelixis, Inc. (EXEL) Target Amid CRC Caution - MSN
Live Scanner Shows Breakout on Exelixis Inc.Portfolio Return Summary & Weekly Breakout Opportunity Watchlist - newsimpact.co.kr
Exelixis reports Q2 rev. below consensus, net product revenues 2% lower YoY. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc.EXEL - FinancialContent
H.C. Wainwright Maintains Buy on Exelixis (EXEL) Despite STELLAR-305 Phase 3 Setback - MSN
Signal strength of Exelixis Inc. stock in tech scannersInflation Watch & Community Shared Stock Ideas - Newser
H.C. Wainwright Maintains Buy Rating on Exelixis Despite STELLAR-305 Phase 3 Setback - AInvest
What makes Exelixis Inc. stock price move sharplyStop Loss & Free Community Supported Trade Ideas - thegnnews.com
Did You Suffer Losses in Exelixis, Inc. (EXEL)? Contact Levi & Korsinsky About Securities Fraud Claims - ACCESS Newswire
Exelixis Q2 net product revs down 2% at $531.3mln, below consensus. - AInvest
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc.EXEL - MarketScreener
Momentum Screeners Rank Exelixis Inc. in Top 5 TodayQuarterly Market Review & Scalable Portfolio Growth Ideas - newsimpact.co.kr
Will Exelixis Inc. continue its uptrendJuly 2025 Action & Expert Curated Trade Setups - Newser
Is it too late to sell Exelixis Inc.Quarterly Growth Report & AI Forecast for Swing Trade Picks - Newser
EXEL Investor Notice: Levi & Korsinsky Investigates Exelixis, Inc. for Securities Law Violations - ACCESS Newswire
Pan-Tumor Rollover Study: Bristol-Myers Squibb, Exelixis, and Novartis Collaborate on Long-Term Cancer Treatment - AInvest
Investigation Underway: Exelixis, Inc. (EXEL)Contact Levi & Korsinsky Over Securities Law Violations - ACCESS Newswire
Exelixis Q2 2025 presentation slides: Cabozantinib franchise grows 19% YoY By Investing.com - Investing.com Canada
Statistical indicators supporting Exelixis Inc.’s strengthJuly 2025 Retail & Fast Entry High Yield Tips - Newser
Exelixis Inc. Builds Base for Possible ReboundJuly 2025 Highlights & Safe Capital Growth Plans - sundaytimes.kr
Exelixis, Inc. (EXEL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Investors in Exelixis, Inc. (EXEL) Warned of Potential Securities FraudContact Levi & Korsinsky Today - ACCESS Newswire
Ongoing Securities Investigation into Exelixis, Inc. (EXEL)Contact Levi & Korsinsky - ACCESS Newswire
Exelixis Gains 15.6% YTD: How Should You Play the Stock? - The Globe and Mail
Exelixis Inc. Rebounds From Oversold Zone — Now What2025 Stock Rankings & AI Forecast for Swing Trade Picks - mustnews.co.kr
Lost Money on Exelixis, Inc. (EXEL)? Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth? - Yahoo Finance
PNC Financial Services Group Inc. Acquires 1,029 Shares of Exelixis, Inc. (NASDAQ:EXEL) - Defense World
Exelixis (EXEL) Price Target Lowered by HC Wainwright, Analysts Maintain Overall Positive Outlook - AInvest
Exelixis, Inc. (EXEL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
What Fibonacci levels say about Exelixis Inc. reboundWeekly Stock Movement Prediction Watchlist - Newser
Exelixis stock price target lowered to $46 at H.C. Wainwright on SCCHN trial halt - Investing.com Nigeria
Exelixis Inc (EXEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Exelixis Inc 주식 (EXEL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| WYSZOMIERSKI JACK L | Director |
Jun 03 '25 |
Sale |
43.09 |
7,535 |
324,683 |
358,882 |
0.94%
1.72%
자본화:
|
볼륨(24시간):